Henryk Fiedorowicz

Prof. Henryk Fiedorowicz

orcid

Research Focus & Metrics

Academic Career Length

44Years (1983-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2013 in Journal of Biomedical Materials Research Part A
Verified
Journal Article
Closed access
IAINAM UL AHAD
INAM UL AHAD
ABAndrzej Bartnik
Andrzej Bartnik
HFHenryk Fiedorowicz
Henryk Fiedorowicz
JKJerzy Kostecki
Jerzy Kostecki
BKBarbara Korczyc
Barbara Korczyc
Dermot BrabazonDermot Brabazon
Dermot Brabazon

1 May 2010 in Nuclear Instruments and Methods in Physics Research Section B: Beam Interactions with Materials and Atoms
Verified
Journal Article
Closed access
PWPrzemyslaw Wachulak
Przemyslaw Wachulak
ABA. Bartnik
A. Bartnik
HFHenryk Fiedorowicz
Henryk Fiedorowicz
PRPiotr Rudawski
Piotr Rudawski
RJR. Jarocki
R. Jarocki
MSM. Szczurek
M. Szczurek

31 May 1993 in Applied Physics Letters
Verified
Journal Article
Closed access
PDF file
HFHenryk Fiedorowicz
Henryk Fiedorowicz
ABA. Bartnik
A. Bartnik
ZPZ. Patron
Z. Patron
PPP. Parys
P. Parys
This letter reports the first study of x-ray emission from plasma produced by laser irradiation of gas puff targets. The gas puff targets were created by the pulsed injection of gas into a vacuum chamber. To irradiate the gas puff target a Nd-glass laser was used, which generated 1-ns pulses of up to 15 J in energy. Spatial, spectral, and temporal measurements show that intense soft x-ray emission from the laser-irradiated gas puff target is produced.

1 October 2000 in Optics Communications
Verified
Journal Article
Closed access
HFHenryk Fiedorowicz
Henryk Fiedorowicz
ABAndrzej Bartnik
Andrzej Bartnik
HDHiroyuki Daido
Hiroyuki Daido
ICIl Woo Choi
Il Woo Choi
MSMasayuki Suzuki
Masayuki Suzuki
SYSusumu Yamagami
Susumu Yamagami

1 February 2000 in Applied Physics B
Verified
Journal Article
Closed access
PDF file
HFHenryk Fiedorowicz
Henryk Fiedorowicz
ABA. Bartnik
A. Bartnik
RJR. Jarocki
R. Jarocki
RRR. Rakowski
R. Rakowski
MSM. Szczurek
M. Szczurek

26 March 2022 in Stem Cells International
Verified
Journal Article
Open access
PDF file
Agata Nowak-StępniowskaAgata Nowak-Stępniowska
Agata Nowak-Stępniowska
POPaulina Osuchowska
Paulina Osuchowska
HFHenryk Fiedorowicz
Henryk Fiedorowicz
ETElżbieta Trafny
Elżbieta Trafny
Hypoxia-mimetic agents are new potential tools in MSC priming instead of hypoxia incubators or chambers. Several pharmaceutical/chemical hypoxia-mimetic agents can be used to induce hypoxia in the tissues: deferoxamine (DFO), dimethyloxaloylglycine (DMOG), 2,4-dinitrophenol (DNP), cobalt chloride (CoCl2), and isoflurane (ISO). Hypoxia-mimetic agents can increase cell proliferation, preserve or enhance differentiation potential, increase migration potential, and induce neovascularization in a concentration- and stem cell source-dependent manner. Moreover, hypoxia-mimetic agents may increase HIF-1α, changing the metabolism and enhancing glycolysis like hypoxia. So, there is clear evidence that treatment with hypoxia-mimetic agents is beneficial in regenerative medicine, preserving stem cell capacities. These agents are not studied so wildly as hypoxia but, considering the low cost and ease of use, are believed to find application as pretreatment of many diseases such as ischemic heart disease and myocardial fibrosis and promote cardiac and cartilage regeneration. The knowledge of MSC priming is critical in evaluating safety procedures and use in clinics. In this review, similarities and differences between hypoxia and hypoxia-mimetic agents in terms of their therapeutic efficiency are considered in detail. The advantages, challenges, and future perspectives in MSC priming with hypoxia mimetic agents are also discussed.